Osimertinib/Tagressa vs. Ametinib: A double-star comparison of targeted therapies for lung cancer

Osimertinib Osimertinib and Almonertinib are both third-generation EGFR-TKI targeted drugs and are widely used in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). The two drugs are similar in mechanism of action and indications, but there are certain differences in efficacy, side effects and accessibility. Patients should carefully consider their own conditions when choosing.

Osimertinib is the world's first approved third-generation EGFR-TKI. It is mainly used for first-line treatment of patients with advanced NSCLC with EGFR exon 19 deletion or exon 21 (L858R) mutation, and second-line treatment of patients with positive EGFR T790M mutation. Its clinical research data shows that osimertinib has excellent performance in progression-free survival (PFS) and overall survival (OS), and has significant efficacy in patients with brain metastases. Ametinib is a third-generation EGFR-TKI independently developed in China. Its indications are similar to osimertinib. It is mainly used for patients with locally advanced or metastatic NSCLC who are positive for the EGFR T790M mutation. Clinical studies have shown that ametinib is equivalent to osimertinib in efficacy and is well tolerated in Asian patients.

In terms of side effects, common adverse reactions of osimertinib and ametinib include diarrhea, rash, oral ulcers and paronychia, etc. Most of them are mild to moderate and can be relieved by symptomatic treatment. However, the incidence of interstitial lung disease (ILD) with osimertinib is slightly higher than that with ametinib, which requires the attention of patients and doctors. In addition, ametinib has a lower risk of abnormal liver function and is more suitable for patients with poor liver function.

In terms of accessibility, osimertinib has been included in the national medical insurance directory, and patients can reimburse part of the cost through medical insurance, significantly reducing the financial burden. As a domestic drug, Ametinib is relatively low-priced and has been included in medical insurance, providing patients with more choices.

Reference materials:https://go.drugbank.com/drugs/DB09330